Autoimmune hepatitis (AIH) is often diagnosed late in the disease course and usually requires lifelong immunosuppressive therapy. Unfortunately, the etiology of the disease and the mechanisms leading to the autoimmune destruction of the liver parenchyma are only poorly understood. For a long time, one reason for this lack of apprehension was the absence of reliable animal models with a chronic immune response against liver tissues. Initial attempts to break tolerance against hepatocytes usually just resulted in mild, transient hepatitis flares. Recently, however, some approaches have been made to establish models of chronic AIH that reflect the immunopathogenic mechanisms seen in humans. In this article, we reflect on recent models, focusing on their feasibility and chances for success in providing a platform for studying the mechanisms of autoimmune liver destruction and the development of possible therapeutic interventions.
often not recognized during early stages. Therefore, it is difficult to obtain information about the immunological reactions responsible for initiation of the disease. Furthermore, it is difficult to obtain samples of intrahepatic lymphocytes or samples from draining lymph nodes to study the immune response. In fact, just a few autoantigens are defined by their T-cell responses, and most of our knowledge about possible hepatic autoantigens stems from investigations of the humoral antiliver immune response. The use of animal models of AIH might therefore improve our understanding of the pathophysiology of the disease and might help to explore new possibilities for therapy and prevention. The use of inbred strains with defined major histocompatibility complex (MHC) restriction further helps to simplify the research of anti-liver immune responses. Certainly, one major goal is to define a relation between pathological reactions of the innate and adaptive immunity and liver autoantigens to substitute the unspecific immune suppression with antigen-specific approaches.
It is important to recapitulate the basis for the development of AIH. It is believed that AIH develops in individuals with a genetic predisposition under the influence of one or probably several environmental factors (Fig. 1) . In human AIH, not much is known about specific environmental factors, although viruses have been suggested in single cases. It seems, rather, that various triggering agents might lead to anti-liver immune reactions seen in AIH in genetically predisposed individuals.
THE LIVER AS TARGET FOR AUTOIMMUNITY
In contrast to other organs, the liver appears more resistant to initiation of autoimmune diseases. The frequency of autoimmune disorders afflicting the liver, such as AIH, 1 primary biliary cirrhosis (PBC), 2 and primary sclerosing cholangitis (PSC), is relatively low compared with other autoimmune diseases, such as thyroiditis (Hashimoto's disease, Grave's disease), celiac disease, type 1 diabetes, multiple sclerosis (MS), and rheumatoid arthritis. In addition, it has been known for a long time that liver allografts are less frequently rejected than other transplants, 3 and some rodent strain combinations even exhibit complete tolerance to liver allografts. 4, 5 This immune privilege of the liver depends on the whole organ because isolated allogeneic hepatocytes are vigorously destroyed. 6 The immune privilege of the liver might have evolved to prevent liver damage because the liver is at the forefront of contact of the immune system with neoantigens. This evolutionary process might be explained by the following: First, because of its function as a detoxifying and drug metabolizing organ, the liver is prone to cellular destruction (i.e., by ethanol) and neoantigen formation (i.e., protein-adduct formation by reactive metabolite 7, 8 ). Both may lead to local inflammation and activation of resident macrophages (i.e., Kupffer cells) and to liver lymphocytes resulting in autoimmune damage to the liver parenchyma. Second, many antigens from the gut and its flora reach the liver immune system via portal drainage in healthy individuals and even more in diseased conditions of the gut, with breakdown of the mucosal barrier. Finally, the high regenerative capacity of the liver enables chronic viral infections, such as hepatitis B virus (HBV) and hepatitis C virus (HCV), without immediate destruction of the target organ. In these situations, however, the immune privilege of the liver might contribute to the lack of control of the infection by the host's adaptive immune system. Several possible explanations for the observed hepatic tolerance have been suggested in the past, including T-cell inactivation by antigenic priming in the liver, 9 tolerance induction via cross-presentation by liver sinusoidal endothelial cells (LSECs), 10 induction of regulatory T cells (T regs ) by LSECs, 11 and hepatic stellate cell (HSC)-induced T-cell apoptosis. 12 The tolerogenic properties of antigens expressed in the liver compared with other sites was recently demonstrated by Lüth et al: Ectopic expression of a neural antigen myelin basic protein (MBP) in the liver resulted in protection from neuroinflammatory disease in a mouse model for MS. 13 It was found that MBP-specific T regs had been generated that blocked the proliferation of MBP-specific effector T cells even when transferred into mice not expressing MBP in the liver. Such T regs have not been generated when MBP was ectopically expressed in the skin. 13 This work suggests that the liver microenvironment provides a milieu that promotes peripheral tolerance and therefore might prevent excessive damage of the liver by autoimmune dysregulations.
Finally, these tolerogenic properties of the liver contributed to difficulty in establishing a reliable animal model for chronic autoimmune liver diseases. Several approaches that have been used for animal models of other autoimmune diseases afflicting organs, such as the pancreas in type 1 diabetes or the central nervous system (CNS) in MS, have failed in the liver in that only transient hepatitis could be observed. . It is supposed that various environmental factors can disturb the balance between proinflammatory effector T cells and regulatory T cells (T regs ) in individuals with a genetic predisposition. Apart from the major histocompatibility complex (MHC) II link, most other genetic associations represent polymorphic variants of common alleles that will together define the genetic risk. Among environmental factors, pathogen infections have been extensively associated with autoimmune diseases. The presence of a structural similarity between pathogen and host, commonly referred to as ''molecular mimicry,'' might be one mechanism involved in the etiology of autoimmunity.
ANIMAL MODELS
Before we report about more recent animal models for AIH, we would like to reflect on the multitude of models that have been described over the last decades. Most of the models use transgenic (Tg) mice that express a variety of target antigens specifically in the liver. In general, such target antigen Tg mice are infected with a pathogen carrying an identical or similar antigen (concept of molecular mimicry) and/or receive an adoptive transfer of target antigen-specific lymphocytes. Unfortunately, only very few models do indeed result in persistent autoimmune liver damage that is comparable to the pathogenesis of human AIH. Often, hepatitis was reported to be only transient with moderately elevated serum aminotransferase levels and mild cellular infiltrations of the periportal region. This is most likely due to the previously mentioned mechanisms of peripheral tolerance induction/maintenance that seem to work more efficiently in the liver compared with other organs.
Even before the widespread use of Tg technology, several models for AIH were developed that used fractions of liver homogenates, mostly of heterologous origin, combined with various activating adjuvants (e.g., complete Freund's adjuvant [CFA] ). Although target antigens of human AIH were largely unknown at that time, such strategies resulted sometimes in prolonged hepatitis flares. However, strong and repetitive stimulations with allogeneic or xenogenic liver proteins were usually necessary, and still chronic hepatitis was never observed. 14 Taken together the initial experiments in rabbits and mice established immunogenic fractions of hepatocytes lysates. They showed the induction of antibodies that usually could not transfer the disease and were proving that hepatocyte damage was induced by T cells.
Further, in the early 1980s, a mouse model termed ''experimental autoimmune hepatitis'' (EAH) 15 was developed in analogy to the experimental autoimmune encephalomyelitis (EAE), which was at that time already widely used as a model for human MS. 16 In this EAH model, Kuriki et al injected smooth muscle antibody (SMA) in mice with syngeneic liver homogenate of liver-specific lipoproteins with the polysaccharide of Klebsiella pneumoniae 03:K1 as adjuvant. Such EAH mice generated liver-specific lipoprotein antibodies and had portal infiltrations of mononuclear cells. 15 Moreover, transfer of splenocytes of EAH mice with features of autoimmune liver disease resulted in portal infiltration with mononuclear cells and necrosis of parenchymal cells in the recipients. 15 Similarly, Lohse et al (1990) induced EAH by immunization of C57BL/6 mice with a crude 100,000 g supernatant of syngeneic liver homogenate (S-100) emulsified in CFA. 17 They demonstrated transient liver damage characterized by perivascular inflammatory infiltrates, hepatocyte necrosis, and a generation of S-100 protein-specific T-cells. 17 Studies in a mouse EAH model by Watanabe et al 18 were remarkable because they found that histological hepatitis, production of autoantibodies to liverspecific protein (LSP), and delayed-type hypersensitivity to LSP were pronounced in mice after neonatal thymectomy. Inbred A/J mice contracted EAH after being injected subcutaneously eight times with syngeneic S-100 extracts. These results are very interesting retrospectively because it was shown by Asano et al 19 that neonatal thymectomy prevents the proper development of the CD4þ CD25þ population of T regs . The data by Watanabe therefore suggest that liver-specific T-cell responses are normally counter regulated by the T regs population. A lack of functional activity by these cells is suspected to be one important determinant for spontaneously occurring autoimmune disease. 20 Later, Lohse and colleagues (1998) 21 also investigated the effectiveness of T-cell vaccination in this model. In T-cell vaccination, activated T cells from organs affected by autoimmune disease are irradiated and used for immunization to evoke an anti-idiotypic regulatory response (probably directed against epitopes of the Vb-chains of the CD4 þ T cells used for immunization presented on the nonvariant MHC I homologue Qa1). 22 Taken together, the experiments on EAH in inbred mice gave valuable information on effector cells and regulatory phenomenon in liver-specific immune reactions, but they did not induce a chronic relapsing AIH. Rather, they have demonstrated the difficulty in breaking tolerance toward liver antigens, and they showed involvement of regulatory mechanisms. The autoantibodies induced were not comparable to autoantibodies in human AIH, and no specific autoantigen was identified. A detailed review of these models was published in an earlier volume of this journal. 23 
CYTOKINE MODELS OF LIVER INJURY
Several mouse models show that high levels of interferon (IFN)g and tumor necrosis factor (TNF)a induced by various triggers can lead to inflammatory lesions, hepatocyte apoptosis, and fulminant hepatic failure. 24 Liverspecific Tg expression of IFNg, driven by the serum amyloid P promoter, led to gradually increasing serum transaminases and hepatitis, with age generating a picture of chronic hepatitis. 25 This is of interest because it has been shown that the number of TNFa and IFNg positive cells within biopsy specimens of patients with AIH correlated with disease activity. 26 Several ways of inducing cytokine-mediated liver injury in mouse models have been described. Systemic application of the leptin concanavalin A (ConA) leads to unspecific T-cell stimulation and severe liver injury, with leukocytes sticking to the endothelial cells. 27 The liver injury does not occur in mice with severe combined immunodeficiency syndrome and is mediated by CD4þ cells and macrophages. The final effector cytokines are TNFa and IFNg because neutralizing antibodies to either cytokine can inhibit the disease. 28, 29 Cytokine production depends on the interaction between lymphocytes and macrophages. 30 One early mediator and subsequent target of activated CD4þ cells seems to be the LSECs that bind ConA preferentially but are subsequently destroyed. 31 Interestingly, CD1d-deficient mice, lacking natural killer T (NKT) cells, are protected from ConA-induced liver injury. 32 Adoptive transfer of hepatic NKT cells isolated from wild-type mice, but not from FasL-deficient gld mice, sensitized CD1d-deficient mice to ConA-induced hepatitis, suggesting FasL expression on liver NKT cells in the pathogenesis of ConA-induced hepatitis. 32 Other polyclonal stimulators of T cells, such as activating anti-CD3 antibodies or the superantigen staphylococcal enterotoxin B, led to massive hepatocyte apoptosis in mice pretreated with the transcriptional inhibitor D-galactosamine. 33 The main effector cytokine in these models seems to be TNFa. In fact, application of TNFa alone in mice sensitized with D-galactosamine leads to hepatic injury. 34 However, ConA-induced hepatitis is a model for acute liver injury mediated by cytokine storm rather than a model of AIH with a chronic liver-specific immune response.
TRANSGENIC MODELS OF AUTOIMMUNE HEPATITIS
For some patients with AIH, humoral target antigens were described. Formiminotransferase cyclodeaminase (FTCD) and cytochrome P450 (CYP) 2D6 35, 36 are specifically expressed in the liver, yet the autoantibodies are not entirely AIH-disease specific. However, antibodies against soluble liver antigen (SLA) are liver disease-specific, but the target antigen is ubiquitously expressed suggesting a liver-specific modification of the target antigen. Yet in the majority of patients the target antigen is unknown. Disease models employing autoantigens of the human disease, which were successful for MS and T1D, were hampered for AIH.
Transgenic technology models with liver-specific expression of neoantigens were generated to mimic the expression of liver-specific autoantigens. In most models, the Tg target antigens were either tolerated or ignored by the host's immune system-even when large numbers of liver-antigen-specific T cells were around due to the combination with MHC I-or MHC II-restricted Tcell receptor (TCR) Tg mice that were specific for the respective neoantigen. In most cases development of hepatitis required pathogen infection, overexpression of inflammatory factors within the liver, or a combination of the two. One major problem of these approaches, however, is that the ectopic expression of the neoantigen in the thymus leads to deletional tolerance of antigen-reactive T cells before they can contact the antigen in the liver. Just a few initial studies investigated thymic expression, and the ones that did often used reverse transcriptase-polymerase chain reaction (RT-PCR) of the whole thymus. We know by now that promiscuous gene expression of peripheral antigens, as well as of organ-specific transgenes, occurs in a small subpopulation of thymic medullary epithelial cells (0.1% of all thymocytes). [37] [38] [39] Promiscuous expression of peripheral antigens in this small number of cells is, nevertheless, sufficient to lead to negative selection of antigen-reactive T cells. 38, 39 In the early 1990s, Frank Chisari's group (as reported in Ando et al 40 and Moriyama et al 41 ) generated Tg mice expressing the hepatitis B virus surface antigen (HBsAg) under the control of the mouse albumin (Alb) promoter as a target antigen, specifically in hepatocytes. To induce autoimmune liver diseases, an adoptive transfer of activated T cells from an HBsAg-primed donor mouse was necessary. The HBsAg-specific immune response was dominated by HBsAg-specific cytotoxic T lymphocytes (CTLs), which triggered apoptosis of hepatocytes expressing HBsAg and released IFNg on antigen encounter. 40 However, only a transient form of hepatic injury was observed, which lasted less than 3 weeks following the transfer of activated HBsAgspecific cells and more resembled a delayed-type hypersensitivity reaction. 40 The first conclusive experiment proving that a neoantigen expressed solely on hepatocytes could lead to tolerance induction of T cells by deletion, anergy, and receptor downregulation came from Ferber et al. 42 The alloantigen H- -reactive Des-TCR on most of their CD8 þ T cells. 42 Part of the tolerance was mediated by downregulation of the TCR, a tolerance mechanism detected earlier as a response to extrathymic expression of a neoantigens. 43 Induction of antigen expression by application of lipopolysaccharide (LPS) led to a further downregulation of the TCR and to the deletion of antigen-specific cells. 44 Furthermore, tolerance induction had to involve induction of anergy as well because there were still Tg T cells with high levels of TCR expression detectable that were nevertheless tolerant. It was shown that constant contact with antigen is necessary to keep these cells tolerant and to prevent TCR upregulation on the reminder cells. 45 This elaborate study was ruling out any influence of ectopic expression of the neoantigen in thymus or hematopoietic antigen-presenting cells (APCs) by creating thymic chimeras and bone marrow chimeras. (Thymectomized CRP-K b mice are engrafted with transgene-negative thymuses and are reconstituted with TCR-Tg bone marrow. 42 ) The authors could readily NEW ANIMAL MODELS FOR AUTOIMMUNE HEPATITIS/CHRISTEN ET AL follow up antigen-specific T cells using a clonotypic marker. 42 The tolerance induction in this model also underscores the tolerogenic potential of the liver 46 because K b expression on b cells in the pancreas led to ignorance of the antigen in a similar model. 47 Later, Limmer and coworkers (1998) showed that tolerance could only be broken after additional transfer of cells expressing the H-2K b target antigen and interleukin (IL)-2, or, alternatively, when mice were infected with a liverspecific pathogen (Listeria monocytogenes), indicating that proinflammatory danger signals within the liver microenvironment were necessary to cause autoimmune tissue damage. 48 In a follow-up article by the same authors (2002), it was demonstrated that injection of immunostimulatory cytosine phosphate guanine-rich oligodeoxynucleotides (CpG-ODNs) in H-2K b /TCR-double-Tg mice is sufficient to activate H-2K b -specific CD8 T cells, which then subsequently attack H-2K b -expressing hepatocytes. 49 The H-2K b -specific T cells are very potent and appear in the liver of H-2K b -Tg mice as early as 2 hours after adoptive transfer. 50 However, chronic hepatic damage (>8 weeks) could only be observed after repetitive administration of CpG-ODN, and termination of this inflammatory stimulus resulted in abrogation of disease. These findings indicated that additional factors are required for the self-perturbation of autoimmunity. 49 Bertolino et al 51 used H-2K b expression-driven by the metallothionein promoter (Met-K b mice) and the Des-TCR-Tg T cells-to follow the liver-specific immune response. Because negative selection by thymic expression in this model was shown, 52 they created thymic chimeras (thymectomized Met-K b mice engrafted with a non-Tg thymus and reconstituted with Des-TCR-Tg bone marrow). They showed spontaneously marked hepatic infiltrates 3 to 5 weeks after bone marrow reconstitution that were gradually diminishing. 51 Despite similar numbers of Des-TCR-Tg T cells in the thymuses of Met-K b mice and control mice, their number was reduced in the periphery in Met-K b mice, suggesting deletion of these cells. Adoptive transfer of post-thymic Des-TCR-Tg T cells into Met-K b mice showed an expansion and subsequent deletion of TCR-Tg T cells as described previously. 53 This was accompanied by hepatic infiltrates that gradually disappeared. Although it was suggested that hepatocytes can induce tolerance as an active mechanism by expansion and subsequent deletion of autoreactive cells, tolerance to any other allotransplants was not demonstrated in this model. 51 It was subsequently shown with in vitro experiments that hepatocytes expressing H-2K b can efficiently prime naïve CD8 þ cells despite their lack of co-stimulatory molecules. Yet hepatocytes fail to promote survival signals (IL-2 and bclxl signals induced by CD28 interaction), so that the primed T cells die by neglect 54 and not by Fas or TNFa-mediated activation-induced cell death. 55 More recently, Derkow et al generated Tg TF-OVA and ASBT-OVA mice, which express the model antigen ovalbumin (OVA) under control of the transferrin (TF) promoter or the apical sodium-dependent bile transporter (ASBT) promoter specifically in hepatocytes or cholangiocytes, respectively. 56 The authors adoptively transferred TCR-Tg CD8 T cells (OT-I) or CD4 T cells (OT-II) and found that only OT-I T cells migrated to the liver in TF-OVA as well as ASBT-OVA mice, where they proliferated and caused inflammation and acute liver injury. 56 However, the elevation of serum aminotransferases and cellular infiltration lasted for only 1 to 2 weeks post-transfer. 56 Several models used an adoptive transfer of target antigen-specific, mostly TCR-Tg T cells in combination with an infection with liver-tropic viruses, bacteria, or parasites. Such pathogen infection targeting the liver can cause a local ''fertile field,'' 57 resulting in enhanced attraction of potentially aggressive cells of the immune system. The model by Voehringer et al demonstrated that breaking of T-cell ignorance to a viral (transgene) antigen in the liver could induce hepatitis only after infection of the liver. 58 They used Tg mice expressing the immunodominant CTL epitope GP 33 of the glycoprotein (GP) of the lymphocytic choriomeningitis virus (LCMV) under the control of the Alb promoter exclusively in the liver. Such Alb-LCMV mice did not show any signs of hepatitis at that stage and even adoptive transfer of TCR-Tg, GP 33 specific T cells was not sufficient to induce disease. However, when these mice were infected with LCMV after adoptive transfer of TCR-Tg cells, a transient form of hepatitis developed. 58 This approach is similar to the rat insulin promoter (RIP)-LCMV mouse model for type 1 diabetes, where GP is expressed under the control of the RIP specifically in the insulin-producing b-cells in the pancreas. 59, 60 However, in contrast to the Alb-LCMV model, the classical RIP-LCMV model does not require transfer of LCMV-specific T cells. 59, 61, 62 Another possibility of generating a fertile field is the delivery of inflammatory factors directly in the target organ. Delivery of the inflammatory cytokine IL-12 by direct intraperitoneal injection or DNA vaccination has proved to be effective in eliciting liver damage in combination with the expression of a target antigen in the liver. [63] [64] [65] Interleukin 12 has been demonstrated to play a central role in the development of many autoimmune diseases in experimental models, including type 1 diabetes, experimental autoimmune uveitis, and autoimmune thyroid disease. [66] [67] [68] Djilali-Saiah used IL-12 to elicit hepatic damage in transthyretin (TTR)-LCMV mice, which express the well-characterized nucleoprotein (NP) of LCMV as a target antigen under control of the TTR promoter specifically in the liver. 63 Liver injury characterized by cellular infiltration and elevated serum aminotransferase levels was induced by DNA vaccination with plasmids encoding the NP and IL-12 genes.
An NP-specific CTL response was detectable after 2 months and persisted up to 5 months postvaccination. 63 However, serum aminotransferase levels were not increased before month 5, and only minor cellular infiltrates were detectable in the liver. 63 Thus, coexpression of the inflammatory cytokine IL-12 was required for hepatic damage In a subsequent study by the same group, coexpression of IL-12 together with CYP2D6 resulted in significant inflammation in the liver, but DNA vaccination with the CYP2D6-plasmid alone did not have the same result. 64 However, only minor elevations in serum alanine aminotransferase (ALT) and a transient generation of anti-CYP2D6 antibodies with large inter-individual differences have been reported. 64 Expression of IL-12 was also important in another model that followed an entirely different approach to induce autoimmune liver inflammation. Tamaki et al used dendritic cell (DCs) loaded with well-differentiated hepatocellular carcinoma (Hepa) 1-6 cells (DC/Hepa1-6) for vaccination of wild-type C57BL/6 mice followed by intraperitoneal injection of recombinant human IL-12. 65 The DC/Hepa1-6-vaccinated mice showed liverspecific inflammation, and S-100-stimulated splenocytes showed a proliferative and cytotoxic response. Further, adoptive transfer of such DC/Hepa1-6-activated splenocytes into nonvaccinated recipients resulted in liver damage if mice had been pretreated with IL-12. 65 Recently, Zierden et al presented a poster at a monothematic conference of the European Association for the Study of the Liver (EASL) in Hamburg, Germany reporting a spontaneous chronic liver inflammation in Alb-HA/CL4-TCR double Tg mice. 69 The Alb-HA/CL4-TCR mice expressed the influenza virus hemagglutinin (HA) under control of the Alb promoter specifically in the liver, as well as HA-specific TCR in the majority of CD8 T cells. This model was insofar spontaneous in that no liver-tropic infection was needed to elicit persistent hepatitis, suggesting that the presence of a large quantity of liver antigen-specific CD8 T cells is sufficient to elicit chronic liver inflammation. 69 However, even though the liver displayed portal and lobular infiltrations, only a mild increase of serum ALT was found. Interestingly, most of the infiltrating HA-specific CD8 T cells displayed impaired proliferative capabilities and only little effecter function. In addition, the liver infiltrates contained considerable numbers of CD4 T regs that suppressed the activation of HA-specific CD8 T cells in vitro. 69 Thus, T regs seem to play a role in suppressing the ongoing autoimmune liver disease, thereby preventing a full-blown autoimmune destruction of the liver parenchyma.
One possibility for the lack of persistence of hepatic damage after initial acute phase of liver injury in some of the models discussed in this section might be the choice of the target antigen. In most cases, target proteins have been used that have been well-characterized in other models for autoimmune disease, such as the RIP-LCMV model for type 1 diabetes, 59 ,60 but had no association with human autoimmune liver disease. Therefore, we used human CYP2D6, which is the immunodominant antigen in human AIH type 2, 35, 36 as an inducing antigen, which confers molecular mimicry to the mouse CYP P450 isoforms. It was delivered to the liver by infection with a human CYP2D6-expressing adenovirus.
THE CYP2D6 MOUSE MODEL
Infections are prime candidates for initiating autoimmunity in genetically predisposed individuals because they frequently induce strong inflammatory responses in various organs and can attract a multitude of potentially autoaggressive lymphocytes to the site of infection. 61 One possible mechanism by which viruses could induce autoimmunity is a structural similarity of virus and host components, a phenomenon commonly referred to as ''molecular mimicry'' 70 . It has been demonstrated that molecular mimicry may be involved in the induction, acceleration, and prevention of autoimmune processes. [71] [72] [73] [74] [75] Alternatively, autoimmunity can be the consequence of heterologous immunity, in which structurally unrelated peptide epitopes can be recognized by the same TCR due to the degeneracy of the TCR-MHC-peptide interaction. The possible importance of such heterologous immunity in liver diseases was demonstrated by the simultaneous detection of an influenza peptide and an HCV peptide by human T cells.
We applied the concept of molecular mimicry by combining infection of the liver with the delivery of a ''viral'' antigen (human CYP2D6) that mimics mouse liver antigens (mouse CYP homologues) (Fig. 2) . Infection of wild-type FVB mice with an adenovirus expressing human CYP2D6 (Ad-CYP2D6) resulted in the breakdown of natural tolerance to the mouse CYP homologues. We observed long-lasting hepatic damage, characterized by massive subcapsular liver fibrosis; extensive subcapsular and perivascular infiltration by B cells, CD4 and CD8 T cells, macrophages, and DCs; and transiently elevated serum aminotransferase levels. 76 Importantly, Ad-2D6-infected mice develop high titers of anti-CYP2D6 antibodies and recognize the same immunodominant epitope recognized by AIH type 2 patients. 76 In addition, infection with Ad-2D6 led to the activation of CYP2D6-specific CD4 and CD8 T cells, which were found in threefold excess in the liver compared with the spleen (Holdener and Christen, unpublished observation). Furthermore, infection of CYP2D6 mice with Ad-CYP2D6 caused an activation of HSCs and subsequently persistent fibrosis, which was localized predominantly in the subcapsular area (Hintermann and Christen, unpublished observation).
Interestingly, Ad-2D6-infection of humanized CYP2D6 mice-the human CYP2D6 was transgenically expressed under control of its own promoter predominantly in the liver, 77 the anti-CYP2D6 titers were much lower, and the frequency of CYP2D6 T cells was massively decreased resulting in a reduced severity of liver damage and fibrosis. 76 These data indicate that the peripheral tolerance to human CYP2D6 is much tighter in humanized CYP2D6 mice compared with wild-type mice. The molecular mimicry approach, which uses similar antigens as target and trigger, seems to be more successful in inducing autoimmunity than molecular identity using exactly matching antigens. At least in the liver, this circumstance might be an explanation of why models that use an approach of molecular identity like the H-2K b -mouse, 48 the HBsAg-mouse, 40 or the Alb-LCMV-mouse 58 depend on the transfer of highly reactive TCR-Tg T cells and often fail in establishing chronic autoimmune liver disease.
Recently, we also succeeded in the induction of a chronic hepatitis by infection with an adenovirus expressing the human antigen FTCD. The hepatitis very much depended on the genetic background of the mouse strain. Hepatitis could just be induced in the autoimmune-prone nonobese diabetic (NOD) mouse strain and did not develop in FVB/N, C57/BL6, or BALB/c. 78 This underlines the hypothesis that autoimmunity just develops in genetically predisposed individuals. Interestingly, autoimmunity did not develop after infection with an adenovirus expressing SLA on any of the genetic backgrounds despite the presence of autoantibodies against SLA and the development of antinuclear autoantibodies. 78 Apart from the polygenetic background of autoimmune diseases, single gene defects may also cause AIH, such as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) syndrome, which is described in another article in this issue. Also, autoimmune regulator (AIRE) knockout mice also show spontaneous large hepatic infiltrates on selected background strains (Jaeckel, unpublished observation).
SUMMARY
In summary, most of the animal models for AIH require hepatic inflammation to induce liver damage ( Fig. 3 provides a schematic summary) . Such a fertile field for the development of autoimmunity can be Infection of humanized cytochrome P450 (CYP)2D6 mice results in a persistent, but relatively mild form of AIH. Similar to other models using Tg mice (see B-E), a preestablished tolerance to the target antigen seems to prevent the development of severe autoimmune liver disease. (G) In contrast, Ad-2D6-infection of wild-type mice expressing the mouse CYP isoenzymes, which are similar but not identical to human CYP2D6, results in an accelerated form of persistent AIH with massive infiltrations, extensive fibrosis, high-titer anti-CYP2D6 antibodies, and high frequencies of CYP2D6-specific T cells in the liver. Thus, the similarity of human CYP2D6 to the mouse CYP homologues seems to be substantial enough to induce an anti-CYP2D6 immune response, but also distant enough from identity to circumvent peripheral tolerance in the liver.
achieved by delivery of inflammatory cytokines, such as IL-12, by simple intraperitoneal injection 65 and plasmid vaccination 63, 64 ; or by infection with a liver-tropic pathogen, such as adenovirus, 76 Listeria monocytogenes, 48 or LCMV. 58 In contrast to other model systems, the CYP2D6 model that has been developed in our laboratory 76 builds on the concept of molecular mimicry rather than identity to overcome immunological tolerance in the liver. This approach has been successful in establishing a model for chronic rather than transient hepatic damage. The CYP2D6 model reflects many features of human AIH, such as the generation of high-titer anti-CYP2D6 antibodies as well as CYP2D6-specific T cells. 76 Thus, the use of a true human autoantigen, such as CYP2D6 76 or FTCD, 78 may be important for establishing a model that comes close to the immunopathogenesis of autoimmune liver disease as observed in patients with AIH. Such models should therefore provide a platform to investigate mechanisms involved in the immunopathogenesis of autoimmune-mediated chronic hepatic injury as seen in human AIH and to evaluate possible ways of therapeutic interference. 
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